Long-term effects of patiromer for hyperkalaemia treatment in patients with mild heart failure and diabetic nephropathy on angiotensin-converting enzymes/angiotensin receptor blockers: Results from AMETHYST-DN

ESC Heart Failure

Volumn 5, Issue 4, 2018, Pages 592-602

  Pitt, Bertram ^a   Bakris, George L ^b   Weir, Matthew R ^c   Freeman, Mason W ^d   Lainscak, Mitja ^e   Mayo, Martha R ^f   Garza, Dahlia ^f   Zawadzki, Rezi ^f   Berman, Lance ^f   Bushinsky, David A ^g  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e General Hospital Murska Sobota   (Slovenia)

^f Vifor (International) Inc   (Switzerland)

^g UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Heart failure; Hyperkalaemia; Patiromer; RAASi

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PATIROMER; POTASSIUM; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; LOSARTAN; SPIRONOLACTONE;

AGED; ARTICLE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; HYPERKALEMIA; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; CONTROLLED STUDY; DOSE RESPONSE; FOLLOW UP; HEART STROKE VOLUME; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TIME FACTOR; TREATMENT OUTCOME;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BIOMARKERS; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FOLLOW-UP STUDIES; HEART FAILURE; HYPERKALEMIA; LOSARTAN; POTASSIUM; RETROSPECTIVE STUDIES; SPIRONOLACTONE; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME;

EID: 85051100646     PISSN: None     EISSN: 20555822     Source Type: Journal    
DOI: 10.1002/ehf2.12292     Document Type: Article

References (35)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: An update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol 2016; 22: 659–669.
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Rouilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force Members, Document Reviewers. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18:891–975.
3. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–1321.
4. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709–717.
5. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, EMPHA-SIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11–21.
6. Kuijvenhoven MA, Haak EA, Gombert-Handoko KB, Crul M. Evaluation of the concurrent use of potassium-influencing drugs as risk factors for the development of hyperkalemia. Int J Clin Pharm 2013; 35: 1099–1104.
7. Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol 2012; 109: 1510–1513.
8. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009; 169: 1156–1162.
9. Pitt B, Bakris GL. New potassium binders for the treatment of hyperkalemia: current data and opportunities for the future. Hypertension 2015; 66: 731–738.
10. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin– angiotensin–aldosterone system. N Engl J Med 2004; 351: 585–592.
11. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC. Use of aldosterone antagonists in heart failure. JAMA 2009; 302: 1658–1665.
12. Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly: drugs exacerbate impaired potassium homeosta-sis. J Gen Intern Med 1997; 12: 646–656.
13. Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin– angiotensin system: meta-analysis of randomised trials. BMJ 2013; 346: f360.
14. Epstein M, Pitt B. Recent advances in pharmacological treatments of hyperkalemia: focus on patiromer. Expert Opin Pharmacother 2016; 17: 1435–1448.
15. Li L, Harrison SD, Cope MJ, Park C, Lee L, Salaymeh F, Madsen D, Benton WW, Berman L, Buysse J. Mechanism of action and pharmacology of patiromer, a nonabsorbed cross-linked polymer that lowers serum potassium concentration in patients with hyperkalemia. J Cardiovasc Pharmacol Ther 2016; 21: 456–465.
16. Veltassa (patiromer) for oral suspension [package insert]. Redwood City, CA: Relypsa, Inc.; 2016.
17. European Medicines Agency. Veltassa. http://www.ema.europa.eu/ema/index. jsp?curl=pages/medicines/human/medicines/004180/human_med_ 002141.jsp&mid= WC0b01ac058001d124. (24 August 2017).
18. Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, Christ-Schmidt H, Berman L, Weir MR. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail 2015; 17: 1057–1065.
19. Bushinsky DA, Williams GH, Pitt B, Weir MR, Freeman MW, Garza D, Stasiv Y, Li E, Berman L, Bakris GL. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia. Kidney Int 2015; 88: 1427–1433.
20. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ, PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J 2011; 32: 820–828.
21. Bakris GL, Pitt B, Weir MR, Freeman MW, Mayo MR, Garza D, Stasiv Y, Zawadzki R, Berman L, Bushinsky DA, AMETHYST-DN Investigators. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial. JAMA 2015; 314: 151–161.
22. ICH Harmonised Tripartite Guideline. Guideline for good clinical practice E6. International Conference on Harmonisation; 1996.
23. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191–2194.
24. Directive 2001/20/EC of the European Parliament and of the Council. 2001.
25. Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, Wittes J, Christ-Schmidt H, Berman L, Pitt B, Investigators OPAL-HK. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med 2015; 372: 211–221.
26. Bushinsky DA, Spiegel DM, Gross C, Benton WW, Fogli J, Hill Gallant KM, Du Mond C, Block GA, Weir MR, Pitt B. Effect of patiromer on urinary ion excretion in healthy adults. Clin J Am Soc Nephrol 2016; 11:1769–1776.
27. Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Wil-liams GH. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin–angiotensin system inhibitors. Kidney Int 2016; 90: 696–704.
28. Weir MR, Spiegel DM, Wilson D, Benton WW, Yuan J, Gross C. Aldosterone, renin and blood pressure during patiromer treatment of hyperkalemia in CKD. J Am Soc Nephrol 2016; 17:201A.
29. The SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302.
30. Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin–angiotensin–aldosterone system inhibitors. Am J Manag Care 2015; 21: S212–S220.
31. Epstein M, Alvarez PJ, Reaven NL, Funk SE, McGaughey KJ, Brenner MS, Benton W, Golestaneh L. Evaluation of clinical outcomes and costs based on prescribed dose level of renin– angiotensin–aldosterone system inhibitors. Am J Manag Care 2016; 22: S313–S326.
32. Chernin G, Gal-Oz A, Ben-Assa E, Schwartz IF, Weinstein T, Schwartz D, Silverberg DS. Secondary prevention of hyperkalemia with sodium polystyrene sulfonate in cardiac and kidney patients on renin–angiotensin–aldosterone system inhibition therapy. Clin Cardiol 2012; 35: 32–36.
33. Hagan AE, Farrington CA, Wall GC, Belz MM. Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. Clin Nephrol 2016; 85: 38–43.
34. Harel Z, Harel S, Shah PS, Wald R, Perl J, Bell CM. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med 2013; 126: 264.e9–e24.
35. Kayexalate (Sodium Polystyrene Sulfo-nate) Cation-Exchange Resin [Prescribing Information]. Bridgewater, NJ: sanofi-aventis; 2010.